Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (332)	5/17/2004 8:43:20 AM
From: mopgcw	Read Replies (2) \| Respond to of 590

ssb on asco: Amgen (AMGN)/Abgenix (ABGX): Another EGF-R inhibitor of interest is the fully human monoclonal antibody called ABX-EGF being developed by Amgen and Abgenix. Full details from a Phase II study of Amgen/Abgenix's ABX-EGF as a monotherapy in refractory colorectal cancer patients will be presented at this meeting. As a reminder, interim results were presented on the first 44 patients (40 evaluable) at the 2003 ASCO meeting, which demonstrated a 9-10% response rate, a similar response rate that has been demonstrated with commercially-available Bristol-Myers Squibb's Erbitux, a chimeric monoclonal antibody. Last year, this study was expanded to enroll approximately 100 patients, including patients failing an Eloxatin-based chemotherapy regimen called FOLFOX, which has been become more broadly utilized. As a reminder, in late January, Abgenix announced that a pivotal Phase III trial of ABX-EGF as a monotherapy in advanced colorectal cancer patients had been initiated by partner, Amgen. A second pivotal study has also been initiated in Europe. In our opinion, the initiation of these pivotal studies imply that the results from the Phase II study were sufficiently positive to proceed with these studies. Amgen and Abgenix indicated that the study design was reviewed and approved by the FDA under a Special Protocol Assessment (SPA) with the plan to submit an application under accelerated approval guidelines. As a reminder, an SPA provides clear regulatory guidelines of approval if a study as followed under its submitted design achieves the targeted endpoints. We believe the study is designed to be conducted in patients who have become refractory to oxaliplatin (Sanofi Synthelabo's Eloxatin) as a third line therapy. Earlier this year, Eloxatin was approved as a first line treatment for metastatic colorectal cancer in combination with Fluorouracil (5-FU) and Leucovorin (LV). While the exact details of the pivotal study for ABX-EGF have not been provided, we believe that the trial is targeted to enroll a couple of hundred patients with potential endpoints of response rate, duration of response and tumor progression. Other endpoints may include survival. We estimate that the study is likely to complete enrollment this year with a potential for submission next year leading to a possible approval in late 2005 or early 2006.